Evaluation and Management of Focal FDG-Avid Splenic Lesions in Lymphoma
In lymphoma patients with a focal FDG-avid splenic lesion, the lesion should be interpreted as lymphomatous involvement if the FDG uptake is greater than liver uptake, and biopsy should be considered only when the diagnosis is uncertain or when it would change management.
Diagnostic Approach
Initial Interpretation Using PET-CT
The Lugano Classification provides clear guidance for interpreting splenic lesions in lymphoma 1:
- Focal FDG uptake in the spleen consistent with lymphoma based on distribution and/or CT characteristics should be considered lymphomatous involvement during staging
- Splenic involvement is best determined by PET-CT and may present as:
- Focal nodular lesions (as in your case)
- Multiple lesions
- Homogeneous splenomegaly
- Diffuse infiltration with miliary lesions
- Large solitary mass 1
Quantitative Assessment
Research evidence supports specific thresholds for distinguishing benign from malignant splenic lesions:
- SUVmax > 5.3 has 90.3% sensitivity and 80.6% specificity for malignancy 2
- SUVmax > 2.3 in patients with known FDG-avid malignancy achieves 100% sensitivity and specificity 3
- Visual assessment: Splenic lesion uptake greater than liver uptake is highly predictive of malignancy 3, 4
Important caveat: In lymphoma specifically, PET-CT demonstrated 100% accuracy for identifying splenic disease, superior to CT's 57% accuracy 4. This makes PET-CT the gold standard for splenic evaluation in lymphoma.
Management Algorithm
When to Accept the Lesion as Lymphoma (No Biopsy Needed)
- Patient has confirmed FDG-avid lymphoma (DLBCL, follicular lymphoma, or other FDG-avid histologies) 5
- Focal splenic uptake exceeds liver uptake on visual assessment 1, 3
- SUVmax > 2.3 (or ideally > 5.3 for higher specificity) 2, 3
- Distribution and CT characteristics consistent with lymphoma 1
- No clinical features suggesting infection or other etiology 1
When to Consider Biopsy or Further Evaluation
The Lugano Classification specifically states: "If uncertain regarding etiology of new lesions, biopsy or interval scan may be considered" 1.
Consider biopsy when:
- Atypical presentation for the known lymphoma histology
- Isolated splenic lesion without other sites of disease
- Clinical suspicion of alternative diagnosis (infection, abscess, other malignancy)
- Result would change management (e.g., distinguishing transformation in indolent lymphoma) 5
Critical pitfall: False-positive FDG uptake can occur with granulomatous diseases 3. In patients without known malignancy, 80% of FDG-avid splenic masses were malignant, but 20% were benign inflammatory conditions 3.
Role of PET-CT in Guiding Biopsy
The 2023 EANM guidelines strongly recommend (consensus score 9.0): "PET-CT can guide biopsy in indolent lymphoma if there is a suspicion of transformation" 5. This principle applies to splenic lesions—if biopsy is needed, PET-CT identifies the optimal site with highest metabolic activity.
Response Assessment Implications
For staging purposes, the Lugano Classification is clear 1:
- Focal FDG-avid splenic lesions meeting criteria are considered sites of disease and should be included in staging
- Splenic involvement affects stage (Stage IV if isolated, or contributes to overall disease burden)
- Lesions should be documented as measurable or non-measurable disease for response assessment
Special Considerations
Diffuse vs. Focal Uptake: Distinguish focal lesions from diffuse splenic uptake, which may represent:
- Reactive changes from chemotherapy 1, 6
- Reticuloendothelial system activation 6
- True lymphomatous infiltration
Bone marrow correlation: The guidelines note that staging with PET-CT can show bone marrow involvement and replace bone marrow biopsy in most patients with DLBCL 5. Similar logic applies to splenic involvement—if clearly FDG-avid and consistent with lymphoma, tissue confirmation is often unnecessary.
Practical Recommendation
For your patient with lymphoma and a focal FDG-avid splenic lesion near the spleen: Interpret this as lymphomatous involvement if uptake exceeds liver, document it in staging, and proceed with systemic therapy appropriate for the lymphoma histology and stage. Biopsy is unnecessary unless the clinical picture is atypical or the finding would fundamentally alter treatment strategy.